{
  "docId": "019de077-4c75-7299-85f2-8570aa012761",
  "docSlug": "bc27eff688e591dce79cc29b4a79cc4b",
  "documentTitle": "Starboard Value | Activist Presentation Deck | 74 slides",
  "authorId": "starboard-value",
  "authorName": "Starboard Value",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2024-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 68,
  "pageCount": 74,
  "prevPage": 67,
  "nextPage": 69,
  "slideType": "revenue_buildup",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 6,
  "notes": "The slide uses a waterfall chart to critique capital allocation efficiency.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-4c75-7299-85f2-8570aa012761/68",
  "deckHref": "/decks/019de077-4c75-7299-85f2-8570aa012761",
  "deckJsonHref": "/decks/019de077-4c75-7299-85f2-8570aa012761.json",
  "deckAnchorHref": "/decks/019de077-4c75-7299-85f2-8570aa012761#slide-68",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.65,
        "y": 0.5
      },
      "kind": "callout",
      "text": "We need management focused on achieving at least 38% revenue growth return and the Board focused on accountability and raising expectations",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1c72d264-47ae-4c8e-9e17-aef9b84c39de",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.08,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Pfizer Sales Bridge (Ex. COVID): 2023 to 2030",
      "attrs": null,
      "subkind": "waterfall-bridge",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f8fcedb7-863b-41ca-be0a-dc96892bac5c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.01,
        "y": 0.97
      },
      "kind": "disclaimer",
      "text": "Source: Public company filings, Wall Street Research, Visible Alpha, and Starboard estimates.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "384a5449-8479-4154-b6ce-da29c27c19c2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.65,
        "y": 0.35
      },
      "kind": "table",
      "text": "Gross Revenue Growth $19 billion; R&D and M&A $128 billion; Revenue Return 15%",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "22696c7b-3a91-4f18-9e11-5fd4e2e558e9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.94,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Adjusting For LOEs, Pfizer Is Currently Expected to Grow by $19 Billion of Revenue From 2023 to 2030",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6d6667ae-1058-4fbb-b20d-ad5ba3eb5331",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "waterfall-bridge",
      "slug": null,
      "matchId": "bd4a767d-6ba1-46f1-aef1-248e5d71a6ab",
      "evidence": "Visual representation of revenue growth components",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 73,
      "from": 61,
      "beatId": "09329c98-b3dc-4181-a1f0-2064b6b5f307",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document proposes a solution by suggesting that the Board needs to hold management accountable for improving performance and achieving higher revenue growth.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 70,
      "from": 66,
      "name": "Mece Breakdown",
      "slug": "40-mece-breakdown",
      "bestFor": "Problem structuring, ensuring completeness, strategic analysis",
      "matchId": "3e7f589c-1016-46fa-a786-ecdd6d3310b8",
      "evidence": "The document proposes a breakdown of Pfizer's R&D investments and suggests that the company needs to achieve higher revenue growth based on its R&D and M&A investments.",
      "position": 2,
      "objective": "How can Pfizer improve its return on R&D investments?",
      "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage",
      "confidence": 0.6,
      "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}